Federated Investors Inc. PA Boosts Holdings in NewLink Genetics Corporation (NLNK)

Federated Investors Inc. PA grew its holdings in NewLink Genetics Corporation (NASDAQ:NLNK) by 20.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,076 shares of the biotechnology company’s stock after acquiring an additional 12,168 shares during the period. Federated Investors Inc. PA owned about 0.25% of NewLink Genetics Corporation worth $537,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also bought and sold shares of the company. Wells Fargo & Company MN grew its stake in shares of NewLink Genetics Corporation by 3.0% in the first quarter. Wells Fargo & Company MN now owns 162,926 shares of the biotechnology company’s stock worth $3,926,000 after acquiring an additional 4,701 shares in the last quarter. Driehaus Capital Management LLC acquired a new position in shares of NewLink Genetics Corporation in the first quarter worth $5,127,000. Northwest Wealth Management LLC grew its stake in shares of NewLink Genetics Corporation by 3.1% in the second quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock worth $426,000 after acquiring an additional 1,740 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of NewLink Genetics Corporation in the first quarter worth $443,000. Finally, Bank of America Corp DE grew its stake in shares of NewLink Genetics Corporation by 361.8% in the first quarter. Bank of America Corp DE now owns 31,911 shares of the biotechnology company’s stock worth $769,000 after acquiring an additional 25,001 shares in the last quarter. Institutional investors and hedge funds own 54.78% of the company’s stock.

Shares of NewLink Genetics Corporation (NLNK) opened at 11.31 on Thursday. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. The stock’s market capitalization is $332.75 million. The stock’s 50 day moving average is $8.77 and its 200 day moving average is $12.66.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million during the quarter, compared to analyst estimates of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. Equities research analysts expect that NewLink Genetics Corporation will post ($2.82) earnings per share for the current fiscal year.

WARNING: “Federated Investors Inc. PA Boosts Holdings in NewLink Genetics Corporation (NLNK)” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/21/federated-investors-inc-pa-boosts-holdings-in-newlink-genetics-corporation-nlnk.html.

NLNK has been the subject of several research reports. ValuEngine downgraded shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Jefferies Group LLC set a $7.00 price target on shares of NewLink Genetics Corporation and gave the stock a “hold” rating in a research note on Friday, August 25th. Zacks Investment Research upgraded shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Wednesday, June 7th. Cantor Fitzgerald restated a “buy” rating and issued a $26.00 price target on shares of NewLink Genetics Corporation in a research note on Friday, September 8th. Finally, Robert W. Baird upgraded shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $8.00 to $22.00 in a research note on Friday, September 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $24.17.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corporation (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply